ATNF vs. SPRB, SYBX, GOVX, NRSN, BMRA, EGRX, HCWB, CING, MTVA, and CRVO
Should you be buying 180 Life Sciences stock or one of its competitors? The main competitors of 180 Life Sciences include Spruce Biosciences (SPRB), Synlogic (SYBX), GeoVax Labs (GOVX), NeuroSense Therapeutics (NRSN), Biomerica (BMRA), Eagle Pharmaceuticals (EGRX), HCW Biologics (HCWB), Cingulate (CING), MetaVia (MTVA), and CervoMed (CRVO). These companies are all part of the "pharmaceutical products" industry.
180 Life Sciences vs.
180 Life Sciences (NASDAQ:ATNF) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, institutional ownership, dividends, media sentiment, valuation, analyst recommendations, profitability, earnings and risk.
Spruce Biosciences received 37 more outperform votes than 180 Life Sciences when rated by MarketBeat users. Likewise, 54.93% of users gave Spruce Biosciences an outperform vote while only 28.57% of users gave 180 Life Sciences an outperform vote.
4.1% of 180 Life Sciences shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 0.2% of 180 Life Sciences shares are held by company insiders. Comparatively, 9.1% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, 180 Life Sciences had 1 more articles in the media than Spruce Biosciences. MarketBeat recorded 2 mentions for 180 Life Sciences and 1 mentions for Spruce Biosciences. 180 Life Sciences' average media sentiment score of 0.00 equaled Spruce Biosciences'average media sentiment score.
Spruce Biosciences has a consensus price target of $2.38, indicating a potential upside of 465.48%. Given Spruce Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Spruce Biosciences is more favorable than 180 Life Sciences.
180 Life Sciences has higher earnings, but lower revenue than Spruce Biosciences.
180 Life Sciences has a beta of 0.12, meaning that its share price is 88% less volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.37, meaning that its share price is 137% more volatile than the S&P 500.
180 Life Sciences has a net margin of 0.00% compared to Spruce Biosciences' net margin of -555.23%. Spruce Biosciences' return on equity of -62.10% beat 180 Life Sciences' return on equity.
Summary
Spruce Biosciences beats 180 Life Sciences on 10 of the 13 factors compared between the two stocks.
Get 180 Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
180 Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ATNF) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ATNF Stock Alerts